-+ 0.00%
-+ 0.00%
-+ 0.00%

CytoSorbents Says Q3 Operating Cash Flow Reaches Breakeven Excluding Restructuring Payments

PUBT·11/19/2026 12:06:33
Listen to the news
CytoSorbents Says Q3 Operating Cash Flow Reaches Breakeven Excluding Restructuring Payments
  • CytoSorbents reported third-quarter 2026 positive operating cash flow of approximately $43,000, excluding approximately $251,000 in restructuring payments.
  • Total cash burn, including restructuring payments, was approximately $200,000; cash, cash equivalents and restricted cash totaled approximately $5.7 million.
  • Operating loss narrowed 59% to $1.2 million, reflecting lower expenses and improved gross margin.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CytoSorbents Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-129936), on November 19, 2026, and is solely responsible for the information contained therein.